DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a molecular diagnostics company operating in the dermatology and precision medicine sector, focused on non-invasive skin genomics technology for the detection of skin cancers including melanoma. The company filed a 10-Q with the SEC on November 14, 2018, under accession number 0001144204-18-059952, reflecting its status as a reporting company during its SPAC-related transition period. DermTech reached the public markets through a blank-check company combination, with the process advancing through 2018 and into 2019. Its Smart Sticker platform represents its core commercial asset in early-stage diagnostic dermatology. For full filing history, deal structure, and sponsor data on DMTK, sign up for complete access at SpacDesk.